Krystal(US:KRYS)2025-05-06 14:20VYJUVEK Commercial Performance and Expansion - VYJUVEK has generated over $429 million in revenue since its launch[15] - Q1 2025 net revenue reached $88.2 million, a 95% increase compared to Q1 2024[16, 18] - The gross margin for Q1 2025 was 94%, with a gross to net of 17%[18] - Over 540 reimbursement approvals have been secured as of April 2025, with 45% from commercial payers and 39% from Medicaid[24, 25] - 97% of covered lives under commercial and Medicaid plans have positive access[25] Clinical Development Programs - Four clinical readouts are expected in 2025 for KB407 (cystic fibrosis), KB408 (AATD lung disease), KB304 (aesthetic skin conditions), and KB803 (ocular DEB)[19] - A Phase 1/2 study evaluating KB801 for neurotrophic keratitis is underway, with the first patient expected to be dosed this month[43] - Initial KB408 molecular data showed 35% AAT positive cells at baseline increasing to 39% after KB408 in patient 07[37] Financial Stability - The company's cash and investments totaled $7653 million as of March 31, 2025[54] - Non-GAAP R&D and SG&A expense guidance for the full year 2025 is $150 million to $175 million[55]